Tumour necrosis factor binding ligands
AssigneeArana Therapeutics Limited
InventorsDeborah A. Rathjen, Roger Aston
Life of this patent
Estimating the term…
Abstract
The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
Claims130
An isolated antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein the antibody or fragment thereof competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
A composition comprising an isolated antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein the antibody or fragment thereof competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
An isolated single chain antibody that specifically binds to mature human TNF-α,
- wherein the antibody competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
A composition comprising an isolated single chain antibody that specifically binds to mature human TNF-α,
- wherein the antibody competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
An isolated single domain antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein the antibody or fragment thereof competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
A composition comprising an isolated single domain antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein the antibody or fragment thereof competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.
An isolated antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the antibody or fragment thereof competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α;
- and,
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
A composition comprising an isolated antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the antibody or fragment thereof competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α, and,
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
The composition according to any one of 52-60, wherein the antibody is a humanized antibody.
An isolated single chain antibody that specifically binds to mature human TNF-α,
- wherein when the antibody binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the antibody competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α;
- and,
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
A composition comprising an isolated single chain antibody that specifically binds to mature human TNF-α,
- wherein when the antibody binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the isolated antibody competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α;
- and
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
An isolated single domain antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the isolated antibody or fragment thereof competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α;
- and,
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
A composition comprising an isolated single domain antibody or fragment thereof that specifically binds to mature human TNF-α,
- wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited,
- wherein the antibody or fragment thereof competitively inhibits a second antibody or fragment thereof for specific binding to mature human TNF-α;
- and,
- wherein the second antibody is MAb 42 (ECACC Accession No. 89080304).
Dependencies are inferred from the claim text.